Biognosys
Schlieren
About Biognosys
Biognosys believe that the decoding of the proteome will impact the life sciences more than the genome revolution a decade ago, and they strive to be the company that enables the routine analysis of proteomes in each research and clinical laboratory worldwide.Biognosys offers a unique next-generation solution for precise quantification of large proteomes in biological samples. Their technology provides unprecedented depth and quality of protein expression data for more effective biomarker and drug-target discovery and validation. Biognosys is a spin-off from the leading proteomics lab of Prof. Ruedi Aebersold, ETH Zurich.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $9.0M
- Funding stage: M&A
- Last round: Series G (Aug 2019)
- Website: biognosys.com
- Phone: 41 44 738 20 40
Industries & Categories
Biotechnology, Clinical Trials, Communities, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/biognosys-14126 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.